Abstract
Dyslipidemias are comorbidities in seropositive patients under highly active antiretroviral therapy (HAART), which increase their risk of complications and reduce their life expectancy. Objective: evaluate the frequency and development of dyslipidemias in seropositive patients with highly active antiretroviral therapy (HAART). Material and method: retrospective cohort study, in recently diagnosed HIV+ patients: 366 men and 59 women. Serum concentrations of total cholesterol (TC), triglycerides (TGC), HDL cholesterol (HDL-c) and LDL cholesterol (LDL-c) were evaluated before starting and at month 6, 24, 36 and 48 with HAART. Results: in both sexes at the beginning of the HAART, 67.1% of low HDL-C levels were obtained. Dyslipidaemia due to TGC and TC increased significantly in all participants after 48 months of HAART (36.9% vs. 52.7% and 7.1% vs. 22.4%, respectively, p<0.05). however, the HDL-C decreased in patients with nucleoside and non-nucleoside reverse transcriptase inhibitor drugs. Discussion: HIV+ patients with HAART have a higher risk of developing dyslipidaemia, an increase in concentrations occurred after 6 months of treatment, a trend that continued positive until 48 months with HAART. Conclusions: dyslipidemias due to TG and TC, as well as low HDL-C are the most frequent in HIV+ patients, which change depending on the time and the type of drug indicated in the HAART.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call